Digital Gene AI

Based in Shanghai, China, Digital Gene AI is a high-tech company specializing in AI-driven solutions for drug discovery and skincare innovation, enhancing efficiency in identifying new targets and compounds. Digital Gene AI, founded in 2021, is focused on developing advanced technologies for drug discovery and skincare formulations. The company has engaged in one funding deal, with its most recent funding event occurring on June 2, 2026. The founder's background is currently not disclosed, and there are no mentions of subsidiaries or pivots in business strategy.

Shanghai Shuyin Intelligent Technology Co. , Ltd. specializes in offering advanced AI solutions for drug discovery and skincare innovation. Their platform integrates computational biology with high-throughput omics to enhance the identification of drug targets and compounds.

They also provide siRNA-based skincare ingredients aimed at whitening and anti-aging, primarily catering to pharmaceutical and cosmetic manufacturers in North America, Europe, and parts of Asia. The revenue model of Shanghai Shuyin Intelligent Technology Co. , Ltd. is centered around B2B transactions, collaborating with pharmaceutical and cosmetic companies.

Their business involves direct contracts and licensing agreements for proprietary technology, allowing access to customized siRNA products. Specific pricing structures are undisclosed, but the company has established its presence in the pharmaceutical and cosmetic sectors by offering efficient solutions. In June 2026, Digital Gene AI raised an undisclosed amount of Pre-A funding from multiple investors, including Lingang Digital Technology Fund and Grand Neobay Venture Capital. This funding will support the expansion of the R&D team, upgrade its AI drug discovery platform, and advance its new drug pipeline.

The company has plans to design upcoming products and expand into new markets to meet increasing demands.